DrugPatentWatch Database Preview
RASUVO Drug Profile
see a sample report or, see our see our flat-rate plans
When do Rasuvo patents expire, and what generic alternatives are available?
Rasuvo is a drug marketed by Medac Pharma Inc and is included in one NDA. There is one patent protecting this drug.
This drug has twenty-seven patent family members in nineteen countries.
The generic ingredient in RASUVO is methotrexate. There are twenty drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the methotrexate profile page.
Summary for RASUVO
| International Patents: | 27 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 98 |
| Clinical Trials: | 1 |
| Patent Applications: | 4,293 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for RASUVO |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for RASUVO |
| DailyMed Link: | RASUVO at DailyMed |
Generic Entry Opportunity Date for RASUVO
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for RASUVO
| Drug Class | Folate Analog Metabolic Inhibitor |
| Mechanism of Action | Folic Acid Metabolism Inhibitors |
Medical Subject Heading (MeSH) Categories for RASUVO
Synonyms for RASUVO
| (+)-4-Amino-10-methylfolic acid |
| (2S)-2-[(4-([(2,4-DIAMINOPTERIDIN-6-YL)METHYL](METHYL)AMINO)PHENYL)FORMAMIDO]PENTANEDIOIC ACID |
| (2S)-2-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}phenyl)formamido]pentanedioic acid |
| (2S)-2-[[[4-[(2,4-diamino-6-pteridinyl)methyl-methylamino]phenyl]-oxomethyl]amino]pentanedioic acid;hydrate |
| (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methyl-amino]benzoyl]amino]glutaric acid;hydrate |
| (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methyl-amino]benzoyl]amino]pentanedioic acid |
| (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid |
| (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid;hydrate |
| (2S)-2-[[4-[[2,4-bis(azanyl)pteridin-6-yl]methyl-methyl-amino]phenyl]carbonylamino]pentanedioic acid;hydrate |
| (4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)benzoyl)-L-glutamic acid |
| (S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic acid |
| (S)-2-(4-[(2,4-DIAMINO-PTERIDIN-6-YLMETHYL)-METHYL-AMINO]-BENZOYLAMINO)-PENTANEDIOIC ACID |
| [3H]-methotrexate |
| [3H]methotrexate |
| 1082707-84-3 |
| 133073-73-1 |
| 15475-56-6 (hydrochloride salt) |
| 1771-EP0930075A1 |
| 1771-EP2269989A1 |
| 1771-EP2269994A1 |
| 1771-EP2270001A1 |
| 1771-EP2270008A1 |
| 1771-EP2270018A1 |
| 1771-EP2270505A1 |
| 1771-EP2272825A2 |
| 1771-EP2272827A1 |
| 1771-EP2272832A1 |
| 1771-EP2275413A1 |
| 1771-EP2275420A1 |
| 1771-EP2277565A2 |
| 1771-EP2277566A2 |
| 1771-EP2277567A1 |
| 1771-EP2277568A2 |
| 1771-EP2277569A2 |
| 1771-EP2277570A2 |
| 1771-EP2277865A1 |
| 1771-EP2277876A1 |
| 1771-EP2280012A2 |
| 1771-EP2281563A1 |
| 1771-EP2281815A1 |
| 1771-EP2287156A1 |
| 1771-EP2289892A1 |
| 1771-EP2289894A2 |
| 1771-EP2292233A2 |
| 1771-EP2292280A1 |
| 1771-EP2292595A1 |
| 1771-EP2292614A1 |
| 1771-EP2292615A1 |
| 1771-EP2292617A1 |
| 1771-EP2295055A2 |
| 1771-EP2295416A2 |
| 1771-EP2295426A1 |
| 1771-EP2295427A1 |
| 1771-EP2298743A1 |
| 1771-EP2298748A2 |
| 1771-EP2298764A1 |
| 1771-EP2298765A1 |
| 1771-EP2298768A1 |
| 1771-EP2298772A1 |
| 1771-EP2298778A1 |
| 1771-EP2298780A1 |
| 1771-EP2301928A1 |
| 1771-EP2301933A1 |
| 1771-EP2305243A1 |
| 1771-EP2305640A2 |
| 1771-EP2305642A2 |
| 1771-EP2305660A1 |
| 1771-EP2305668A1 |
| 1771-EP2305671A1 |
| 1771-EP2305679A1 |
| 1771-EP2305689A1 |
| 1771-EP2308833A2 |
| 1771-EP2308839A1 |
| 1771-EP2308855A1 |
| 1771-EP2308861A1 |
| 1771-EP2311453A1 |
| 1771-EP2311807A1 |
| 1771-EP2311808A1 |
| 1771-EP2311825A1 |
| 1771-EP2311827A1 |
| 1771-EP2311829A1 |
| 1771-EP2311840A1 |
| 1771-EP2311842A2 |
| 1771-EP2311850A1 |
| 1771-EP2314590A1 |
| 1771-EP2316459A1 |
| 1771-EP2316832A1 |
| 1771-EP2316833A1 |
| 1771-EP2316834A1 |
| 1771-EP2371811A2 |
| 1771-EP2374454A1 |
| 1dhi |
| 1dhj |
| 2,2'-(9,10-anthracenediylidene)-bis-propanedinitrile |
| 2drc |
| 4-Amino-10-methylfolic acid |
| 4-Amino-10-methylfolic acid hydrate |
| 4-amino-N(10)-methylpteroylglutamic acid |
| 4-Amino-N(sup 10)-methylpteroylglutamic acid |
| 4-Amino-N10-methylpteroyl-L-glutamic acid |
| 4-Aminomethylpteroylglutamic acid |
| 4kn0 |
| 4ocx |
| 59-05-2 |
| 5947-EP0930075A1 |
| 5947-EP2269994A1 |
| 5947-EP2289892A1 |
| 70359-39-6 |
| 73M731 |
| 7413-34-5 (di-hydrochloride salt) |
| A-2190 |
| A-Methopterin |
| A-Methpterin |
| AB02593 |
| Abitrexate |
| Abitrexate (Methotrexate) |
| AC1L2R79 |
| ACT03341 |
| AI3-25299 |
| AJ-26587 |
| AK-77824 |
| AKOS016340329 |
| Amethopterin |
| Amethopterin L- |
| Amethopterine |
| An-PDN |
| Antifolan |
| Antifolan hydrate |
| ANW-72813 |
| AOB5585 |
| APC-2002 |
| Arbitrexate |
| BC202627 |
| BDBM18050 |
| BDBM66082 |
| BIDD:PXR0175 |
| Bio-0134 |
| Bio1_000486 |
| Bio1_000975 |
| Bio1_001464 |
| BR-77824 |
| BRD-K59456551-001-09-3 |
| Brimexate |
| C01937 |
| C20H22N8O5 |
| CAS-59-05-2 |
| CCG-35800 |
| CCRIS 1109 |
| CHEBI:44185 |
| CHEMBL34259 |
| cid_126941 |
| cid_165528 |
| CL 14377 |
| CL-14377 |
| CS-1732 |
| CTK1G9789 |
| D00142 |
| D07ALU |
| D0D3DU |
| D0SV8E |
| DB00563 |
| DivK1c_000114 |
| DL-4-Amino-N10-methylpteroylglutamic acid hydrate |
| DL-Amethopterin hydrate |
| DR002811 |
| DSSTox_CID_822 |
| DSSTox_GSID_20822 |
| DSSTox_RID_75810 |
| DTXSID4020822 |
| EINECS 200-413-8 |
| EMT 25,299 |
| Emtexate |
| Emthexat |
| Emthexate |
| EU-0100020 |
| Fauldexato |
| FBOZXECLQNJBKD-ZDUSSCGKSA-N |
| Folex |
| Folex Pfs |
| Folex-Pfs |
| folic acid antagonist |
| FT-0082628 |
| FT-0601523 |
| g301 |
| Glutamic acid, N-(p-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)-, L- |
| Glutamic acid,4-diamino-6-pteridinyl)methyl] methylamino]benzoyl]-, L-(+)- |
| GTPL4674 |
| GTPL4815 |
| Hdmtx |
| HE357164 |
| HMS1568K12 |
| HMS2095K12 |
| HMS2233O18 |
| HMS3260C21 |
| HMS500F16 |
| HSDB 3123 |
| HY-14519 |
| I06-2098 |
| I14-18123 |
| IDI1_000114 |
| Intradose-MTX |
| Intrathecal methotrexate |
| J10045 |
| KBio1_000114 |
| KBio2_002338 |
| KBio2_004906 |
| KBio2_007474 |
| KBio3_001493 |
| KBioGR_001172 |
| KBioSS_002341 |
| KS-00000L8X |
| KS-5093 |
| KSC269O8T |
| Kyselina 4-amino-N(sup 10)-methylpteroylglutamova |
| Kyselina 4-amino-N(sup 10)-methylpteroylglutamova [Czech] |
| Kyselina N-(p-((2,4-diamino-6-pteridinylmethyl)methylamino)benzoyl)-L-glutamova |
| Kyselina N-(p-((2,4-diamino-6-pteridinylmethyl)methylamino)benzoyl)-L-glutamova [Czech] |
| L-(+)-AMETHOPTERIN |
| L-(+)-N-(p-(((2,4-Diamino-6-pteridinyl)methyl)methylamino)benzoyl)glutamic acid |
| L-Amethopterin |
| L-Glutamic acid,4-diamino-6-pteridinyl)methyl]- methylamino]benzoyl]- |
| L-Glutamic acid,N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-,hydrate(9ci) |
| L-Glutamicacid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]- |
| L-METHOTREXATE |
| Lantarel |
| Ledertrexate |
| Lopac0_000020 |
| LP00020 |
| LS-249 |
| Lumexon |
| Maxtrex |
| MCULE-6523054194 |
| Medsatrexate |
| Metatrexan |
| Metex |
| Methoblastin |
| Methotextrate |
| Methotrate |
| Methotrexat |
| Methotrexat-Ebewe |
| methotrexate |
| Methotrexate 100mg |
| Methotrexate - Abitrexate |
| Methotrexate (JP17/USP/INN) |
| Methotrexate [USAN:INN:BAN:JAN] |
| Methotrexate [USAN:USP:INN:BAN:JAN] |
| Methotrexate 1.0 mg/ml in Dimethyl Sulfoxide |
| Methotrexate for peak identification, European Pharmacopoeia (EP) Reference Standard |
| Methotrexate for system suitability, European Pharmacopoeia (EP) Reference Standard |
| Methotrexate hydrate |
| Methotrexate Lpf |
| Methotrexate Preservative Free |
| METHOTREXATE SODIUM |
| METHOTREXATE SODIUM PRESERVATIVE FREE |
| Methotrexate, European Pharmacopoeia (EP) Reference Standard |
| Methotrexate, L- |
| Methotrexate, pharmaceutical secondary standard; traceable to USP and PhEur |
| Methotrexate, PharmaGrade, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production, meets EP, USP testing specifications |
| Methotrexate, United States Pharmacopeia (USP) Reference Standard |
| METHOTREXATEHYDRATE |
| Methotrexatum |
| Methotrexatum [INN-Latin] |
| Methoxtrexate |
| Methylaminopterin |
| Methylaminopterin hydrate |
| Methylaminopterin; MTX |
| METHYLAMINOPTERINE |
| Methylaminopterinum |
| Metolate |
| Metotressato |
| Metotressato [DCIT] |
| Metotrexato |
| Metotrexato [INN-Spanish] |
| Metrotex |
| Mexate |
| Mexate-Aq |
| Mexate-Aq Preserved |
| MFCD00150847 |
| MLS000049968 |
| MLS001401431 |
| MLS002154208 |
| MolPort-003-665-521 |
| MPI-2505 |
| MPI-5004 |
| MTX |
| MTX hydrate |
| N-(4-(((2,4-Diamino-6-pteridinyl)methyl)methylamino)benzoyl)-L-glutamicacid |
| N-(4-(((2,4-DIAMINO-6-PTERIDINYL)METHYL)METHYLAMINO)BENZOYL)L-GLUTAMIC ACID |
| N-(4-{[(2,4-Diaminopteridin-1-Ium-6-Yl)methyl](Methyl)amino}benzoyl)-L-Glutamic Acid |
| N-(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}benzoyl)-L-glutamic acid |
| N-(p-(((2,4-Diamino-6-pteridinyl)methyl)methylamino)benzoyl)-L-(+)-glutamic acid |
| N-(p-(((2,4-Diamino-6-pteridyl)methyl)methylamino)benzoyl)glutamic acid |
| N-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}phenyl)carbonyl]-L-glutamic acid |
| N-[4-[[(2,4-Diamino-6-pteridinyl)methyl] methylamino]benzoyl]-L-glutamic acid |
| N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid |
| N-{4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]benzoyl}-L-glutamic acid |
| N-Bismethylpteroylglutamic acid |
| NCGC00025060-01 |
| NCGC00025060-02 |
| NCGC00025060-03 |
| NCGC00025060-04 |
| NCGC00025060-05 |
| NCGC00025060-06 |
| NCGC00025060-07 |
| NCGC00025060-08 |
| NCGC00025060-09 |
| NCGC00025060-10 |
| NCGC00025060-11 |
| NCGC00025060-12 |
| NCGC00025060-13 |
| NCGC00025060-15 |
| NCGC00025060-16 |
| NCGC00254216-01 |
| NCGC00260705-01 |
| NCI-C04671 |
| NCIMech_000767 |
| NINDS_000114 |
| Novatrex |
| NSC 740 |
| NSC-740 |
| NSC740 |
| Otrexup |
| Otrexup (TN) |
| Prestwick_322 |
| Prestwick0_000135 |
| Prestwick1_000135 |
| Prestwick2_000135 |
| Q-201366 |
| R 9985 |
| Rheumatrex |
| RTR-020497 |
| s1210 |
| SC-19293 |
| SCHEMBL12421860 |
| SCHEMBL3711 |
| SMP2_000020 |
| SMR000112001 |
| SMR000449324 |
| SPBio_001094 |
| SPBio_002149 |
| Spectrum_001836 |
| Spectrum2_001077 |
| Spectrum3_000497 |
| Spectrum4_000616 |
| Spectrum5_000958 |
| TCMDC-125858 |
| Texate |
| Tocris-1230 |
| Tox21_110944 |
| Tox21_110944_1 |
| Tox21_300269 |
| Tox21_500020 |
| Tremetex |
| Trexall |
| Trexeron |
| Trixilem |
| UNII-99ITO15X8S component FBOZXECLQNJBKD-ZDUSSCGKSA-N |
| UNII-YL5FZ2Y5U1 |
| W-105347 |
| W-60383 |
| WLN: T66 BN DN GN JNJ CZ EZ H1N1&R DVMYVQ2VQ |
| WR-19039 |
| X 133 |
| Xatmep |
| Xatmep (TN) |
| YL5FZ2Y5U1 |
| Z1541638527 |
| ZINC1529323 |
US Patents and Regulatory Information for RASUVO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medac Pharma Inc | RASUVO | methotrexate | SOLUTION;SUBCUTANEOUS | 205776-001 | Jul 10, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Medac Pharma Inc | RASUVO | methotrexate | SOLUTION;SUBCUTANEOUS | 205776-007 | Jul 10, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Medac Pharma Inc | RASUVO | methotrexate | SOLUTION;SUBCUTANEOUS | 205776-004 | Jul 10, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Medac Pharma Inc | RASUVO | methotrexate | SOLUTION;SUBCUTANEOUS | 205776-008 | Jul 10, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Medac Pharma Inc | RASUVO | methotrexate | SOLUTION;SUBCUTANEOUS | 205776-002 | Jul 10, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
see a sample report or, see our see our flat-rate plans
International Patents for RASUVO
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Russian Federation | 2009106053 | ➤ Sign Up |
| Cyprus | 1111159 | ➤ Sign Up |
| Germany | 502007005972 | ➤ Sign Up |
| Serbia | 51688 | ➤ Sign Up |
| Germany | 202007019703 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
